FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma
The drug had significant advantages over two other currently used agents in a phase 3 clinical trial.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Seattle Genetics Announces FDA Approval of Adcetris (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2017 Category: Drugs & Pharmacology Source Type: news
EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL
The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news
Trillium begins dosing in Phase I trial of TTI-621 for solid tumours and mycosis fungoides
Clinical stage immuno-oncology company Trillium Therapeutics has begun dosing in its second Phase I clinical trial of TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously accessible solid tumours and mycosis fungoides. (Source: Drug Development Technology)
Source: Drug Development Technology - February 1, 2017 Category: Pharmaceuticals Source Type: news
Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma
Brentuximab vedotin showed clinically superior outcomes compared with standard of care in patients with cutaneous T cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Angimmune ’s Investigational Cutaneous T-cell Lymphoma Disease...
FDA Fast Track Granted to Angimmune(PRWeb September 13, 2016)Read the full story at http://www.prweb.com/releases/angimmune/201609/prweb13679453.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 13, 2016 Category: Pharmaceuticals Source Type: news
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administrat... Biopharmaceuticals, Oncology, FDA Trillium Therapeutics, SIRPaFc, TTI-621, mycosis fungoides (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 17, 2016 Category: Pharmaceuticals Source Type: news
Takeda and Seattle Genetics report positive results from Phase III ALCANZA trial of Adcetris to treat CTCL
Takeda Pharmaceutical and Seattle Genetics have reported positive results from the Phase III ALCANZA clinical trial of Adcetris to treat cutaneous T-cell lymphoma (CTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2016 Category: Pharmaceuticals Source Type: news
Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5... (Source: Family Practice News)
Source: Family Practice News - July 6, 2016 Category: Primary Care Source Type: news
Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5 times, in a large, longitudinal, population-based cohort study.
Psoriasis also was tied to a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 6, 2016 Category: Dermatology Source Type: news
Cutaneous T-Cell Lymphoma: Focus on Targeted AgentsCutaneous T-Cell Lymphoma: Focus on Targeted Agents
This review explores the latest targeted therapies which provide treatment options for patients with advanced cutaneous T-cell lymphoma. Which are currently approved and which are under investigation? American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma
Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news
Dose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell LymphomaDose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell Lymphoma
Romidepsin regimens that employ less-frequent dosing can prolong remission in patients with some subtypes of cutaneous T-cell lymphoma (CTCL), according to a retrospective records review. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
APO866 lacks efficacy in cutaneous T-cell lymphoma
The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology. (Source: MedWire News)
Source: MedWire News - April 7, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news
miRagen begins Phase I trial for MRG-106 to treat cutaneous T-cell lymphoma
US-based miRagen Therapeutics has started a Phase I trial of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, to treat patients with lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2016 Category: Pharmaceuticals Source Type: news
